Clinical Trials Logo

Diabetic Macular Oedema clinical trials

View clinical trials related to Diabetic Macular Oedema.

Filter by:

NCT ID: NCT00148330 Completed - Clinical trials for Diabetic Macular Oedema

Open Label Extension of a Clinical Trial of Intravitreal Triamcinolone for Diabetic Macular Oedema-TDMX Study

Start date: May 2005
Phase: Phase 2/Phase 3
Study type: Interventional

This open label extension will treat all the eyes of study participants with active study medication (intravitreal triamcinolone) as well as standard laser treatment where appropriate. The specific aims will be to test the following hypotheses: - That intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment remains efficacious over five years - That intravitreal triamcinolone for diabetic macular oedema that persists or recurs after laser treatment retains a manageable and acceptable safety profile over five years

NCT ID: NCT00148265 Completed - Clinical trials for Diabetic Macular Oedema

A Multicentre Randomised Clinical Trial of Laser Treatment Plus Intravitreal Triamcinolone for Diabetic Macular Oedema

Start date: April 2005
Phase: Phase 2/Phase 3
Study type: Interventional

This study is likely to identify an improved and economical treatment for diabetic macular oedema, one of the commonest causes of blindness both in Australia and the rest of the world.The specific aims of the study are to test the following hypotheses: - That intravitreal triamcinolone followed by laser treatment results in a greater improvement in visual acuity than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in greater degree of resolution of macular oedema than placebo followed by laser treatment of eyes with macular oedema secondary to diabetes; - That intravitreal triamcinolone followed by laser treatment results in a reduced requirement for further laser treatment to control diabetic macular oedema than placebo followed by laser treatment; - That intravitreal triamcinolone followed laser has a manageable and acceptable safety profile in eyes with diabetic macular edema.